168 related articles for article (PubMed ID: 12949081)
21. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
Coderch C; Morreale A; Gago F
Anticancer Agents Med Chem; 2012 Mar; 12(3):219-25. PubMed ID: 22044006
[TBL] [Abstract][Full Text] [Related]
22. Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.
Sharbeen G; McCarroll J; Liu J; Youkhana J; Limbri LF; Biankin AV; Johns A; Kavallaris M; Goldstein D; Phillips PA
Neoplasia; 2016 Dec; 18(12):753-764. PubMed ID: 27889644
[TBL] [Abstract][Full Text] [Related]
23. Altered molecular properties of tubulin in a multidrug-resistant variant of Chinese hamster cells selected for resistance to vinca alkaloids.
Pain J; Sirotnak FM; Barrueco JR; Yang CH; Biedler JL
J Cell Physiol; 1988 Aug; 136(2):341-7. PubMed ID: 3045133
[TBL] [Abstract][Full Text] [Related]
24. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
[TBL] [Abstract][Full Text] [Related]
25. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.
Geyp M; Ireland CM; Pittman SM
Leukemia; 1996 Mar; 10(3):447-55. PubMed ID: 8642860
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
27. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
28. Vindesine: a new vinca alkaloid.
Bayssas M; Gouveia J; de Vassal F; Misset JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; Hayat M; Mathé G
Recent Results Cancer Res; 1980; 74():91-7. PubMed ID: 7003662
[TBL] [Abstract][Full Text] [Related]
29. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
Chi S; Xie W; Zhang J; Xu S
J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
[TBL] [Abstract][Full Text] [Related]
30. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.
Rivera-Fillat MP; Pallarés-Trujillo J; Domènech C; Grau-Oliete MR
Br J Pharmacol; 1988 Apr; 93(4):902-8. PubMed ID: 3390658
[TBL] [Abstract][Full Text] [Related]
31. Experimental in vivo cross-resistance of vinca alkaloid drugs.
Maral R; Bourut C; Chenu E; Mathe G
Cancer Chemother Pharmacol; 1981; 5(3):197-9. PubMed ID: 7296754
[TBL] [Abstract][Full Text] [Related]
32. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
[TBL] [Abstract][Full Text] [Related]
33. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
[TBL] [Abstract][Full Text] [Related]
34. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
[TBL] [Abstract][Full Text] [Related]
36. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
37. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
Kelly EB; Tuszynski JA; Klobukowski M
J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
[TBL] [Abstract][Full Text] [Related]
38. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
39. Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule.
Ehrhardt H; Schrembs D; Moritz C; Wachter F; Haldar S; Graubner U; Nathrath M; Jeremias I
Blood; 2011 Dec; 118(23):6123-31. PubMed ID: 21926351
[TBL] [Abstract][Full Text] [Related]
40. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
Liaw TY; Chang MH; Kavallaris M
Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
